Budesonide吸入器市場:各產品類型，用量，強度，各流通管道，各地區- 規模，佔有率，展望，機會分析，2022年～2030年

市場動態

由於哮喘發病率和患病率的增加，預計全球對布地奈德吸入器的需求將在預測期內出現顯著增長。

本調查的主要特徵

• 本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球Budesonide吸入器市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
• 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
• 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
• 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球Budesonide吸入器市場的主要參與者之企業簡介。
• 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
• 全球Budesonide吸入器市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者可以透過全球Budesonide吸入器市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。

目錄

第1章 調查目的與前提條件

• 調查目的
• 前提條件
• 簡稱的說明

第2章 市場展望

• 報告內容
• 市場定義和範圍
• 摘要整理
  • 市場概述:各產品類型
  • 市場概述:各劑量
  • 市場概述:各強度
  • 市場概述:各流通管道
  • 市場概述:各地區
• 連貫機遇地圖(COM)

第3章 市場動態，法規，趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機會
• 影響分析
• 市場趨勢
• 主要的發展情形
• 法規情形
• 產品回收
• 流行病學分析
• 技術概要
• PEST分析
• 波特的五力分析

第4章 Budesonide吸入器的全球市場:冠狀病毒(COVID-19)疫情的影響

• 整體影響
• COVID-19對市場的影響

第5章 Budesonide吸入器的全球市場:各產品類型，2017年～2030年

• 吸入器
• 噴霧器

第6章 Budesonide吸入器的全球市場:各用法用量，2017年～2030年

• 氣霧劑
• 乾粉
• 懸浮液
• 噴霧

第7章 Budesonide吸入器的全球市場，強度，2017年～2030年

• 25mg
• 5mg
• 0mg

第8章 Budesonide吸入器的全球市場:各流通管道，2017年～2030年

• 醫院內藥局
• 零售藥局
• 線上藥局

第9章 Budesonide吸入器的全球市場:各地區，2017年～2030年

• 市場佔有率分析，各地區，2022年及2030年(%)
• 與前一年同期比較成長率分析(各地區)，2017年～2030年
• 各地區趨勢
• 北美
  • 市場規模及預測，YoY成長率，各產品類型，2017年～2030年
  • 用量市場規模及預測，與前一年同期比較成長率，2017年-2030年
  • 強度的市場規模及預測，與前一年同期比較成長率，2017年～2030年
  • 市場規模·預測及與前一年同期比較成長率:各流通管道，2017年-2030年
  • 市場規模及預測，與前一年同期比較成長率，各國，2017年～2030年
• 美國
• 加拿大
• 南美
  • 各產品類型市場規模及預測，YoY成長率，2017年～2030年
  • 用量市場規模及預測，與前一年同期比較成長率，2017年～2030年
  • 強度的市場規模及預測，與前一年同期比較成長率，2017年-2030年
  • 市場規模·預測及與前一年同期比較成長率:各流通管道，2017年-2030年
  • 市場規模及預測，與前一年同期比較成長率，各國，2017年～2030年
• 巴西
• 墨西哥
• 阿根廷
• 其他的南美地區
• 歐洲
  • 各產品類型市場規模，預測，及YoY成長率，2017年～2030年
  • 用量市場規模及預測，與前一年同期比較成長率，2017年～2030年
  • 強度的市場規模及預測，與前一年同期比較成長率，2017年-2030年
  • 市場規模·預測及與前一年同期比較成長率:各流通管道，2017年-2030年
  • 市場規模及預測，與前一年同期比較成長率，各國，2017年～2030年
• 英國
• 德國
• 義大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲
• 亞太地區
  • 各產品類型市場規模，預測，及YoY成長率，2017年～2030年
  • 用量市場規模及預測，與前一年同期比較成長率，2017年～2030年
  • 強度的市場規模及預測，與前一年同期比較成長率，2017年-2030年
  • 市場規模·預測及與前一年同期比較成長率:各流通管道，2017年-2030年
  • 各國市場規模及預測，與前一年同期比較成長率，2017年～2030年
• 中國
• 印度
• 日本
• ASEAN
• 澳洲
• 韓國
• 其他亞太地區
• 中東地區
  • 各產品類型市場規模，預測，及YoY成長率，2017年～2030年
  • 用量市場規模及預測，與前一年同期比較成長率，2017年～2030年
  • 強度的市場規模及預測，與前一年同期比較成長率，2017年～2030年
  • 市場規模·預測及與前一年同期比較成長率:各流通管道，2017年-2030年
  • 市場規模及預測，與前一年同期比較成長率，各國，2017年～2030年
• GCC
• 以色列
• 其他中東地區
• 非洲
  • 各產品類型市場規模·預測及YoY成長率:2017年～2030年
  • 用量市場規模及預測，與前一年同期比較成長率，2017年～2030年
  • 強度的市場規模及預測，與前一年同期比較成長率，2017年～2030年
  • 市場規模·預測及與前一年同期比較成長率:各流通管道，2017年-2030年
  • 市場規模及預測，與前一年同期比較成長率，各國，2017年～2030年
• 北非
• 中非
• 南非

第10章 競爭情形

• 熱圖分析
• 企業簡介
  • Pfizer, Inc.
  • Cipla Limited
  • Lupin Limited
  • Cosmo Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd
  • Manus Aktteva Biopharma LLP
  • Abbott Laboratories
  • Lunan Better Pharmaceutical
  • Novartis International AG(Sandoz)
  • Mylan N.V.
  • Skyepharma
  • AstraZeneca Plc.
  • Chiesi Farmaceutici S.p.A.
  • Orion Corporation
  • Santarus Inc.
  • Synmosa Biopharma Corporation
  • Shanghai Sine Pharmaceutical Laboratories Co. Ltd.

第11章 章節

• 參考文獻
• 調查手法的介紹
• 關於出版社

Budesonide is an artificial glucocorticoid steroid related to the naturally-occurring hormone, cortisol or hydrocortisone, which is produced in the adrenal glands. It is used for treating asthma. Budesonide is sold under the brand name Pulmicort. Each budesonide inhaler is designed to provide 60 to 120 inhalations depending on the device. Increasing air population is expected to lead to high prevalence of asthma worldwide. For instance, on May 11, 2022, according to the World Health Organization (WHO), Asthma is a major non-communicable disease (NCD), affecting both children and adults, and is the most common chronic disease among children globally. Asthma affected an estimated 262 million people in 2019 and caused 455 000 deaths globally. Most asthma-related deaths occur in low- and lower-middle-income countries such as India and Bangladesh, where under-diagnosis and under-treatment is a challenge.

Market Dynamics

The global demand for budesonide inhaler is expected to witness substantial growth over the forecast period, owing to increasing incidences and prevalence of asthma. According to the Global Asthma Report 2018, asthma causes around 1,000 deaths every day and affects as many as 339 million people worldwide.

Increasing product launch by the key market player in expected to boost the growth of global budesonide inhaler market over the forecast period. For instance, in November 2019, Lupin, Pharmaceutical Company, announced the launch of device to track usage pattern of metered-dose inhalers (MDI) by patients suffering from chronic respiratory diseases. The device helped the patients track their metered-dose inhalers (MDI) usage and facilitate improved adherence to therapy. The inhalers are the treatment option for managing chronic respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD).

Key features of the study:

• This report provides an in-depth analysis of the global budesonide inhaler market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 - 2030, considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global budesonide inhaler market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include, Pfizer Inc., Cipla Limited, Lupin Limited, Cosmo Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Manus Aktteva Biopharma LLP, Abbott Laboratories, Lunan Better Pharmaceutical, Novartis International AG (Sandoz), Mylan N.V., Skyepharma, AstraZeneca Plc., Chiesi Farmaceutici S.p.A, Orion Corporation, Santarus Inc., Synmosa Biopharma Corporation, and Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global budesonide inhaler market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global budesonide inhaler market.

Detailed Segmentation:

• Global Budesonide Inhaler Market, By Product type:
  • Inhalants
  • Nebulizer
• Global Budesonide Inhaler Market, By Dosage:
  • Aerosols
  • Dry Powder
  • Suspension
  • Spray
• Global Budesonide Inhaler Market, By Strength:
  • 25 mg
  • 5 mg
  • 0 mg
• Global Budesonide Inhaler Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Budesonide Inhaler Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Europe
    • By Country
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Others By Country/Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Pfizer Inc.*
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Cipla Limited
  • Lupin Limited
  • Cosmo Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd.
  • Manus Aktteva Biopharma LLP
  • Abbott Laboratories
  • Lunan Better Pharmaceutical
  • Novartis International AG (Sandoz)
  • Mylan N.V.
  • Skyepharma,
  • AstraZeneca Plc.
  • Chiesi Farmaceutici S.p.A.
  • Orion Corporation
  • Santarus Inc.
  • Synmosa Biopharma Corporation
  • Shanghai Sine Pharmaceutical Laboratories Co. Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
• Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Dosage
  • Market Snapshot, By Strength
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Landscape
• Product Recall
• Epidemiology Analysis
• Technology Overview
• PEST Analysis
• Porter's Five Forces Model

4. Global Budesonide Inhaler Market - Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• COVID-19 Impact on the market

5. Global Budesonide Inhaler Market, By Product Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Inhalants
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Nebulizers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Budesonide Inhaler Market, By Dosage,2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017- 2030
  • Segment Trends
• Aerosols
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Dry Powder
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Suspension
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Spray
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Budesonide Inhaler Market, By Strength,2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017- 2030
  • Segment Trends
• 25mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• 5mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• 0mg
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Budesonide Inhaler Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million )

9. Global Budesonide Inhaler Market,, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
• UK
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Strength, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million )
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million )
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Heat Map Analysis
• Company Profile
  • Pfizer, Inc.
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
  • Cipla Limited
  • Lupin Limited
  • Cosmo Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd
  • Manus Aktteva Biopharma LLP
  • Abbott Laboratories
  • Lunan Better Pharmaceutical
  • Novartis International AG (Sandoz)
  • Mylan N.V.
  • Skyepharma
  • AstraZeneca Plc.
  • Chiesi Farmaceutici S.p.A.
  • Orion Corporation
  • Santarus Inc.
  • Synmosa Biopharma Corporation
  • Shanghai Sine Pharmaceutical Laboratories Co. Ltd.
• Analyst Views

11. Section

• References
• Research Methodology
• About Us